pharma · Friedreich Ataxia · LRMR
Larimar Therapeutics
Larimar Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Bala Cynwyd, USA
- Founded
- 2016
- Employees
- 82
- Programs
- 3
- Drugs
- 2
- Patents
- 5
Larimar Therapeutics projects
3 ClinicalTrials.gov programs sponsored by Larimar Therapeutics.
Larimar Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Nomlabofusp, Placebo to Nomlabofusp
Larimar Therapeutics
Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.
1 trial -
CTI-1601
Larimar Therapeutics
Friedreich Ataxia
4 trials -
Nomlabofusp
Larimar Therapeutics
Friedreich Ataxia
1 trial
Frequently asked questions
How many clinical projects does Larimar Therapeutics have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.